The award-winning MoveOverMS.org website and MS self™ multiple sclerosis
mobile app featured at Booth #406
ARDSLEY, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (Nasdaq:ACOR),
a biotechnology
company based in New York, will provide demonstrations of its
award-winning digital tools for multiple sclerosis (MS) disease
management at the 2014 Cooperative Meeting of the Consortium of Multiple
Sclerosis Centers (CMSC) and the Americas Committee for Treatment and
Research in Multiple Sclerosis (ACTRIMS), being held May 28–31 in
Dallas, Texas. Demonstrations of MoveOverMS.org and the MS self™ multiple
sclerosis app will be held in the MoveOverMS.org booth (#406) in the
meeting exhibit hall.
MoverOverMS.org offers a multitude of tools to help those living
with MS, including videos, articles and downloadable information.
The MS self mobile app features informative fact cards, achievement
badges, and an interactive journal that allows users to log moods,
thoughts and activities. The app has recently been updated on the iTunes
app store with new features and is free to download.
“We developed MoveOverMS.org and MS self to help people proactively
manage the challenges they face living with MS. We are excited to share
these digital tools with the healthcare professionals attending the
CMSC/ACTRIMS meeting, providing them with additional resources for their
patients,” said
Adrian Rabinowicz
, Acorda’s Senior Vice President,
Clinical Development and Medical Affairs. “Our company’s mission is to
improve the lives of people with neurological disorders. Research and
development of novel medicines is a core component of our mission, as is
providing support to people with MS, their care partners and healthcare
team.”
About CMSC
The Consortium of Multiple Sclerosis Centers (CMSC) is the leading
educational, training, and networking organization for MS healthcare
professionals and researchers. The CMSC’s mission is to promote quality
multiple sclerosis care through educational programming and
accreditation, including live and online events, research grants,
technical journals and papers, and targeted advocacy efforts. The CMSC
member network includes more than 7,000 international healthcare
clinicians and scientists committed to multiple sclerosis care as well
as more than 60 Veterans Administration MS Programs and 225 MS Centers
in the U.S., Canada, and Europe.
About ACTRIMS
The Americas Committee for Treatment and Research in Multiple Sclerosis
(ACTRIMS) provides leadership in the field of multiple sclerosis and
other demyelinating diseases. MS clinicians and researchers founded
ACTRIMS to serve as the U.S. and Canadian counterpart to ECTRIMS, the
European Committee on Treatment and Research in Multiple Sclerosis
(ECTRIMS). The annual ACTRIMS meeting provides a forum to exchange
information, debate current issues, and discuss advances related to
basic and clinical issues in MS research.
About Acorda Therapeutics
Founded in 1995, Acorda
Therapeutics is a biotechnology company focused on developing
therapies that improve the lives of people with neurological disorders.
Acorda markets three FDA-approved therapies including: AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, a treatment to
improve walking in patients with multiple
sclerosis (MS); ZANAFLEX
CAPSULES® (tizanidine hydrochloride) and Zanaflex
tablets, a short-acting drug for the management of spasticity; and QUTENZA®
(capsaicin) 8% Patch for the management of neuropathic pain
associated with postherpetic neuralgia. AMPYRA is marketed outside the
United States as FAMPYRA® (prolonged-release fampridine
tablets) by Biogen Idec under a licensing agreement from Acorda.
Acorda has one of the leading pipelines in the industry of novel
neurological therapies. The Company is currently developing six
clinical-stage therapies and one preclinical stage therapy that address
a range of disorders including post-stroke deficits, epilepsy, stroke,
peripheral nerve damage, spinal cord injury, neuropathic pain, and heart
failure. For more information, please visit the Company’s website at: www.acorda.com.
Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including our ability to successfully market and sell Ampyra in the
U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including Plumiaz (our trade name for Diazepam
Nasal Spray), or any other acquired or in-licensed programs; we may not
be able to complete development of, obtain regulatory approval for, or
successfully market Plumiaz or other products under development; the
occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain regulatory approval of or to successfully
market Fampyra outside of the U.S. and our dependence on our
collaboration partner Biogen Idec in connection therewith; competition,
including the impact of generic competition on Zanaflex Capsules
revenues; failure to protect our intellectual property, to defend
against the intellectual property claims of others or to obtain third
party intellectual property licenses needed for the commercialization of
our products; failure to comply with regulatory requirements could
result in adverse action by regulatory agencies; and the ability to
obtain additional financing to support our operations. These and other
risks are described in greater detail in Acorda Therapeutics' filings
with the Securities & Exchange Commission. Acorda may not actually
achieve the goals or plans described in its forward-looking statements,
and investors should not place undue reliance on these statements.
Forward-looking statements made in this release are made only as of the
date hereof, and Acorda disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this release.
Source: Acorda Therapeutics, Inc.